Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Bristol Myers enters $100M PyroGlu-Ass license agreement with BioArctic
- Bristol Myers added to Analyst Focus List at JPMorgan
- Cytokinetics price target raised to $82 from $80 at RBC Capital
- Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz
